Benign Neoplasm of Salivary Gland, Malignant Neoplasm of Salivary Gland
Conditions
Brief summary
in this resarch we will use ELISA Technique to estimate Human Transcriptional Activator(MYB) Expression .compare it by Immmunohistochemistry analysis of MYB Expression in the malignant and benign salivary gland tumor
Interventions
ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
Sponsors
Cairo University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
. * Patients with clinically evident salivary gland tumors; malignant tumors will be recruited in group I * Benign tumors will be recruited in group II.
Exclusion criteria
* Subjects taking any drugs inducing any changes that could affect the salivary glands. * Pregnant females. * Subjects having any allergies, infectious or autoimmune diseases. * Subjects having any metabolic disorders that can be manifested with salivary gland swelling as diabetes mellitus.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas | two years | Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas. |
Countries
Egypt
Contacts
Primary Contactyousra refaey
Backup ContactFat'heya Zahran
Outcome results
None listed